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Letter to the Editor
Am. J. Hum. Genet. 78:1088, 2006
No Evidence for Association with Parkinson Disease
for 13 Single-Nucleotide Polymorphisms Identified by
Whole-Genome Association Screening
To the Editor:
The 13 SNPs identified by Maraganore et al.1 as being
potentially associated with Parkinson disease (PD [MIM
168600]) represent some of the first fruit produced by
the whole-genome association screening era and are
clearly worthy of follow-up. To further explore these
exciting candidates, we typed each SNP in 538 patients
with idiopathic PD and in 516 control individuals from
the United Kingdom. Cases included 160 patients in-
volved in a community-based epidemiological study of
incident PD and 378 consecutive patients with prevalent
PD attending our research clinic. All cases met United
Kingdom Parkinson’s Disease Society Brain Bank criteria
for the diagnosis of PD. The mean age at disease onset
was 63 years (range 25–91 years); 2% of patients had
early-onset disease (40 years), and 14% of patients
reported a family history of one or more first-degree
relatives with parkinsonian symptoms or tremor. The
control group consisted of 146 spouses of patients with
PD and 370 blood donors. All individuals were white,
except for four patients and one spouse. All gave written
informed consent and a blood sample from which DNA
was extracted using standard methods. Genotyping was
performed using Taqman Assay-on-Demand (rs2245218)
and Assays-by-Design products on a 7900HT Sequence
Detection System (Applied Biosystems). Only samples
that typed successfully for at least one-third of markers
were included in the analysis (520 cases and 499 con-
trols). Genotyping success rates were all 97%, and no
marker showed evidence of deviation from Hardy-Wein-
berg equilibrium. Two pairs of SNPs (rs2313982 and
rs1509269; rs682705 and rs7520966) were found to be
in strong linkage disequilibrium ( , ),′ 2D p 1.0 r 1 0.69
which reduced the number of independent tests to 11.
Allele frequencies in cases and controls were compared
using the COCAPHASE program in the UNPHASED
package.2 Our study provides, on average, 85% power
(range 68%–96%) to detect the case-control differences
averaged over tier 1 and tier 2, as observed by Mara-
ganore et al.1
In our data set, none of the 13 SNPs showed any
evidence of association, all P values being 1.25, even
without correction for multiple testing (tables 1 and 2).
Fewer than half of the SNPs (46%) showed allele fre-
quency differences between cases and controls in the
same direction as that reported by Maraganore et al.1
The combination of our data with those from the orig-
inal report, with the use of the Mantel-Haenszel test
statistic (Statsdirect) and correction for the 11 indepen-
dent tests performed, revealed that only three markers
(rs10200894, ss46548856, and rs7702187) retain any
evidence of significance at the 5% level in the total data
(table 1). In summary, our study suggests that none of
the 13 markers identified by Maraganore et al.1 is as-
sociated with PD.
Under the null hypothesis that there are no genes in-
fluencing susceptibility to PD, a follow-up of 1.4%
(2,734) of the 198,345 markers included in the screening
stage, as performed by Maraganore et al.,1 would be
expected to identify 27–28 markers showing inP ! .01
the replication stage, with half of these—that is, 13–
14—showing an allele frequency difference in the same
direction as that seen in the screening stage. The number
of markers identified by Maraganore et al.1 is, thus, in
keeping with that expected under the null hypothesis.
However, since such screens are not intended to identify
all susceptibility genes and, indeed, would be considered
successful if they identified even a single such locus, we
would not expect to see a striking excess of markers
above the predicted 13. In short, it could be anticipated
that most of the 13 markers identified by Maraganore
et al.1 would be false positives. However, our failure to
replicate results for any of the 13 markers identified by
Maraganore et al.1 suggests that their screen lacked
power in one or more critical dimensions. Although typ-
ing 200,000 markers in 450 cases and controls is a sub-
stantial effort, it is clear that this will adequately inter-
rogate only a part of the common variation in the
genome. Increasing the density of markers and the num-
ber of samples studied would be the most effective way
to increase the power of the study but, in practice, would
be the most difficult. It must remain possible that a more
generous threshold (such as ) would have capturedP ! .1
relevant loci currently lying high in the ranking of mark-
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Table 1
Thirteen SNPs Reported by Maraganore et al.,1 Ranked in Accordance with Evidence for Association in a Meta-Analysis Combined
with Data from This Study
dbSNP
ACCESSION
NUMBER GENE CHROMOSOME POSITION
CONTROL
MAFa
CASE
MAF OR (95% CI)
P
This Studyb Meta-Analysisc
rs10200894 … 2q36 228642637 .09 .08 .91 (.67–1.24) .53 .01
ss46548856d … 10q21 58986929 .10 .09 .92 (.68–1.24) .58 .02
rs7702187 SEMA5A 5p15 9385281 .16 .16 .97 (.76–1.23) .81 .02
rs17329669 … 7p14 36625169 .13 .13 1.04 (.80–1.35) .79 .06
rs7723605 … 5p15 5407615 .13 .14 1.07 (.83–1.39) .59 .06
rs7878232 PASD1 Xq28 150516943 .23 .23 .99 (.78–1.26) .95 .11
rs682705 LOC200008 1p32 54349438 .26 .28 1.08 (.89–1.31) .44 .20
rs7520966 LOC200008 1p32 54357283 .26 .28 1.07 (.88–1.30) .51 .22
rs2245218 PRDM2 1p36 13885132 .16 .14 .89 (.70–1.14) .36 .28
rs2313982 … 4q31 139145665 .09 .08 .83 (.61–1.14) .26 .33
rs1509269 … 4q31 139111329 .12 .12 .92 (.70–1.20) .53 .41
rs11737074 … 4q27 125438978 .23 .21 .90 (.73–1.11) .32 .86
rs16851009 GALNT3 2q24 166456214 .10 .09 .86 (.64–1.16) .33 .94
a Minor-allele frequency.
b P value for comparison of case and control allele frequencies with the use of UNPHASED.2
c P value corresponding to Mantel-Haenszel test statistic for association, with data from this study and that from Maraganore et al.,1
after correction for the number of independent tests.
d Perlegen Sciences internal SNP identifier, as used by Maraganore et al.1
Table 2
Genotype Counts for 13 SNPs Studied
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
ers provided by the screening stage performed by Mar-
aganore et al.1 but falling outside their stringent thresh-
old. On the downside, this approach would greatly in-
crease the number of markers requiring follow-up, gen-
erating a list of nearly 1,000 instead of just 13 potentially
associated loci.
Various strategies for multistage whole-genome as-
sociation studies have been proposed,3–6 and the impor-
tance of setting an appropriate threshold for following
up first-stage results has been stressed. We feel that the
present observations, regarding one of the first whole-
genome association screens performed, strengthen the
importance of these theoretical recommendations. To
ensure that replication and follow-up phases are not
overwhelmingly large, it is essential to ensure high power
in the screening phase. If thresholds as stringent as
are to be used, the screening phase in future PDP ! .01
screens will need to be very much larger than that per-
formed by Maraganore et al.1
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Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMDpsearch
&DBpsnp
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for PD)
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